‘Basaglar,’ price-competitive biosimilar, launched in Korea
‘Basaglar,’ the first insulin glargine biosimilar in Korea, will be launched.
Lilly Korea and Boehringer Ingelheim Korea held a meeting to celebrate the launch of ‘Basaglar(generic name: insulin glargine 100U/ml),’ a insulin glargine biosimilar, on the 13th and revealed the Korean diabetes patie...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.